Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2006 3
2007 6
2008 4
2009 2
2010 3
2011 12
2012 7
2013 9
2014 11
2015 25
2016 10
2017 13
2018 5
2019 8
2020 11
2021 8
2022 5
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Results by year

Filters applied: . Clear all
Page 1
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study.
Song Y, Jin Z, Li ZM, Liu Y, Li L, He C, Su H, Zhou H, Li K, Hao S, Zuo X, Wu J, Li D, Wu M, Sun X, Qi J, Cai Z, Li Z, Li Y, Huang Y, Shen J, Xiao Z, Zhu J. Song Y, et al. Among authors: li z. Clin Cancer Res. 2024 Apr 1;30(7):1248-1255. doi: 10.1158/1078-0432.CCR-23-2582. Clin Cancer Res. 2024. PMID: 38190117 Clinical Trial.
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.
Song Y, Malpica L, Cai Q, Zhao W, Zhou K, Wu J, Zhang H, Mehta-Shah N, Ding K, Liu Y, Li Z, Zhang L, Zheng M, Jin J, Yang H, Shuang Y, Yoon DH, Gao S, Li W, Zhai Z, Zou L, Xi Y, Koh Y, Li F, Prince M, Zhou H, Lin L, Liu H, Allen P, Roncolato F, Yang Z, Kim WS, Zhu J. Song Y, et al. Among authors: li z. Lancet Oncol. 2024 Jan;25(1):117-125. doi: 10.1016/S1470-2045(23)00589-2. Epub 2023 Dec 9. Lancet Oncol. 2024. PMID: 38092009 Clinical Trial.
Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis.
Xu W, Yang S, Zhou K, Pan L, Li Z, Gao S, Zhou D, Hu J, Feng R, Huang H, Wang T, Li D, Ji M, Guo H, Zhao X, Wu B, Yu Y, Wang Y, Huang J, Novotny W, Li J. Xu W, et al. Among authors: li z. Leuk Lymphoma. 2023 Mar;64(3):712-716. doi: 10.1080/10428194.2022.2164692. Epub 2023 Feb 17. Leuk Lymphoma. 2023. PMID: 36799536 No abstract available.
The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial.
Wang T, Sun X, Qiu L, Su H, Cao J, Li Z, Song Y, Zhang L, Li D, Wu H, Zhang W, Li J, Zhou K, Zhou H, Yang Y, Li Z, Cen H, Cai Z, Zhang Z, Fu W, Jin J, Li F, Wu W, Gu X, Zhu W, Liu L, Li Z, Yi S, Bao H, Xu Z, Qiu L. Wang T, et al. Among authors: li z. Clin Cancer Res. 2023 Apr 14;29(8):1440-1449. doi: 10.1158/1078-0432.CCR-22-2939. Clin Cancer Res. 2023. PMID: 36735519 Free PMC article. Clinical Trial.
Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China.
Liu W, Ji J, Zou D, Cao Y, Xu Y, Zhou J, Gao S, Wang F, Chen W, Du J, Zhou H, Zhou F, Shi J, Zhang X, Yang J, Jing H, Jiang Z, Liu H, Li C, Peng H, Jiang S, Wei X, He P, Liu Y, Yang H, Li Z, Huang X, Liu L, Shen L, Liu C, Song Y, Qiu L, Wang X, Ma J, Zhu J. Liu W, et al. Among authors: li z. Bone Marrow Transplant. 2023 Mar;58(3):349-352. doi: 10.1038/s41409-022-01899-w. Epub 2022 Dec 17. Bone Marrow Transplant. 2023. PMID: 36528754 No abstract available.
136 results